1. Home
  2. AJG vs NTRA Comparison

AJG vs NTRA Comparison

Compare AJG & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arthur J. Gallagher & Co.

AJG

Arthur J. Gallagher & Co.

N/A

Current Price

$263.81

Market Cap

55.0B

Sector

Finance

ML Signal

N/A

Logo Natera Inc.

NTRA

Natera Inc.

N/A

Current Price

$332.03

Market Cap

45.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AJG
NTRA
Founded
1927
2003
Country
United States
United States
Employees
706000
N/A
Industry
Specialty Insurers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.0B
45.3B
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
AJG
NTRA
Price
$263.81
$332.03
Analyst Decision
Buy
Strong Buy
Analyst Count
15
15
Target Price
$274.60
$259.07
AVG Volume (30 Days)
1.3M
1.3M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
1.32%
N/A
EPS Growth
N/A
0.65
EPS
4.41
N/A
Revenue
$6,159,600,000.00
$210,939,000.00
Revenue This Year
$30.53
$18.08
Revenue Next Year
$9.13
$19.65
P/E Ratio
$58.87
N/A
Revenue Growth
N/A
N/A
52 Week Low
$190.75
$157.43
52 Week High
$313.55
$333.56

Technical Indicators

Market Signals
Indicator
AJG
NTRA
Relative Strength Index (RSI) 62.86 71.73
Support Level $238.67 $187.64
Resistance Level $269.99 N/A
Average True Range (ATR) 7.13 10.88
MACD 0.24 2.40
Stochastic Oscillator 98.07 96.11

Price Performance

Historical Comparison
AJG
NTRA

About AJG Arthur J. Gallagher & Co.

Founded in 1927 as a one-person agency, Gallagher's primary business is insurance brokerage, with a focus on serving middle-market companies. The company's risk management segment provides third-party claims adjustment to companies that choose to self-insure. Gallagher has about 72,000 employees and generates about a third of its revenue internationally, primarily in Australia, Canada, New Zealand, and the UK.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: